All Stories

  1. Oxygen saturation and mortality for acute pulmonary embolism: multinational retrospective cohort study
  2. Complications in Cancer Associated Thrombosis patients on tinzaparin by cancer site and frailty: a pooled analysis
  3. A simple score to identify the sickest normotensive patients with acute pulmonary embolism
  4. The Ottawa score for prediction of recurrent venous thromboembolism in cancer patients treated with tinzaparin: an individual patient data meta-analysis
  5. miRNAs as Epigenetic Biomarkers for CTEPH: A case-control study towards personalized medicine
  6. Role of Extracellular Vesicles in Chronic Post-Embolic Pulmonary Hypertension: Data from an Experimental Animal Model and Patients
  7. Regional Disparities and Trends in Venous Thromboembolism Mortality in Spain (1999–2022)
  8. Clinically relevant bleeding according to location of metastases in cancer-associated thrombosis
  9. Relevance of recurrent venous thromboembolism according to location of metastasis in patients with cancer-associated thrombosis. A cohort study
  10. Impact of Residual Vein Venous Thrombosis in Consecutive Patients with Cancer-Associated Thrombosis Treated with Tinzaparin—A Cohort Study
  11. Cost-effectiveness of follow-up algorithms for chronic thromboembolic pulmonary hypertension in pulmonary embolism survivors
  12. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID‐19 vaccine
  13. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study
  14. Optimisation of detecting chronic thromboembolic pulmonary hypertension in acute pulmonary embolism survivors: the InShape IV study
  15. Location of metastasis and complications in patients with venous thromboembolism and cancer: a systematic review
  16. Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism
  17. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry
  18. Age and sex differences in pulmonary embolism mortality rates in Spain from 1999 to 2021
  19. Pulmonary embolism: a practical approach to update risk stratification and treatment decisions based on the guidelines
  20. Symptom-related screening programme for early detection of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the SYSPPE study
  21. Anticoagulation and venous thromboembolism in patients aged 90 years and older: Data from the RIETE registry
  22. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding
  23. The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis
  24. When should we involve interventional radiology in the management of acute pulmonary embolism?
  25. Lack of Funding for Direct-Acting Oral Anticoagulants for the Treatment of Pulmonary Embolism in Spain: Why and Until When
  26. Prospective study to evaluate quality of life in amyotrophic lateral sclerosis
  27. Risk factors for pulmonary embolism in lung cancer patients with lower limb deep venous thrombosis: a case-control study
  28. Comparison of long-term complications in cancer patients with incidental and acute symptomatic venous thromboembolism
  29. Feasibility of a screening algorithm for chronic thromboembolic pulmonary hypertension: The OSIRIS study
  30. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
  31. Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study
  32. The rationale, design, and methods of a trial to evaluate the efficacy and safety of oxygen therapy in patients with intermediate-risk acute pulmonary embolism
  33. Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy
  34. Epidemiology of Lung Cancer Mortality in Spain: Updated Information (1982–2021) and Predictions up to 2046
  35. Rate of Recurrence After Discontinuing Anticoagulation Therapy in Patients With COVID-19–Associated Venous Thromboembolism
  36. Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day
  37. Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism
  38. Low-molecular-weight heparin beyond 12 months in patients with cancer-associated thrombosis
  39. COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment
  40. Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism
  41. Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry
  42. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
  43. Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)
  44. Low‐dose apixaban in extended treatment of cancer‐associated thrombosis: Less is more?
  45. Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model
  46. Mechanical Behavior of Calcium Sulphate Modified with Citric Acid and with Added Carbon Fibers
  47. ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly
  48. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
  49. Major bleeding in patients with pulmonary embolism presenting with syncope
  50. Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial
  51. Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
  52. Venous thromboembolism in amyotrophic lateral sclerosis. A prospective quasi-experimental study
  53. Consenso multidisciplinar para el manejo de la tromboembolia de pulmón
  54. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism
  55. Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on At...
  56. Comment on “Severity of pulmonary embolism at initial diagnosis and long-term clinical outcomes: From the COMMAND VTE Registry”
  57. The immune-neuroendocrine system in COVID-19, advanced age and rheumatic diseases
  58. PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19
  59. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism
  60. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation
  61. Analysis of Additives in Gypsum Coatings Based on Melamine, Polycarbonate Salts, Polycarboxylate, and Polycarboxylic Acids
  62. First Detection and Genome Sequencing of SARS-CoV-2 Lambda (C.37) Variant in Symptomatic Domestic Cats in Lima, Peru
  63. Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism
  64. WITHDRAWN: Multidisciplinary consensus for the management of pulmonary thromboembolism
  65. Spanish consensus for the management of pulmonary thromboembolism
  66. Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism
  67. Bleeding risk in hospitalized patients with COVID‐19 receiving intermediate‐ or therapeutic doses of thromboprophylaxis
  68. Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
  69. Trombosis sintomática de la vena ácigos: caso clínico y revisión de la literatura
  70. Timing and characteristics of venous thromboembolism after noncancer surgery
  71. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study
  72. Análisis de las indicaciones y complicaciones de los pacientes con enfermedad tromboembólica venosa a los que se ha colocado filtro de vena cava inferior
  73. Case-Control Analysis of the Impact of Anemia on Quality of Life in Patients with Cancer: A Qca Study Analysis
  74. Repeated Pulses of Methyl-Prednisolone in Adults Hospitalized With COVID-19 Pneumonia and Acute Respiratory Distress Syndrome: A Preliminary Before–After Study (CortiCOVID Study)
  75. Association between Radiotherapy and Risk of Cancer Associated Venous Thromboembolism: A Sub-Analysis of the COMPASS—CAT Study
  76. Deep vein thrombosis and brain metastases. Case report and systematic review
  77. Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study
  78. Comparative clinical prognosis of massive and non‐massive pulmonary embolism: A registry‐based cohort study
  79. Incidental vs. suspected PE in patients with cancer.
  80. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry
  81. Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation
  82. Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts
  83. Thromboprophylaxis after renal transplantation and patient risk stratification: The case of mTOR inhibitors
  84. Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?
  85. Documento de consenso de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) para el seguimiento clínico post-COVID-19
  86. Venous thromboembolism in solid-organ transplant recipients: findings from the RIETE registry
  87. Prognostic Significance of Incidental Deep Vein Thrombosis in Patients with Cancer Presenting with Incidental Pulmonary Embolism
  88. Correlation between short-term air pollution exposure and unprovoked lung embolism. Prospective observational (Contamina-TEP Group)
  89. Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future
  90. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score
  91. Differential biomarker profiles between unprovoked venous thromboembolism and cancer
  92. Screening for occult cancer: where are we in 2020?
  93. Comments on the 2019 ESC guidelines on acute pulmonary embolism
  94. Comentarios a la guía ESC 2019 sobre embolia pulmonar aguda
  95. Association between reperfusion therapy and outcomes in patients with acute pulmonary embolism and right heart thrombi
  96. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry
  97. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
  98. Systolic blood pressure and mortality in acute symptomatic pulmonary embolism
  99. Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project
  100. A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study
  101. Riesgo de recurrencia tras retirada de la anticoagulación en pacientes con enfermedad tromboembólica venosa no provocada: validación externa del nomograma de Viena y del modelo predictivo DASH
  102. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years
  103. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism
  104. Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry
  105. El dilema de la reducción de tratamiento en pacientes con asma moderado-grave controlados
  106. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
  107. Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry
  108. Outcome of pulmonary hypertension associated with respiratory disease
  109. Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin
  110. Extended treatment of cancer-associated thrombosis
  111. Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry
  112. D‐dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry
  113. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry
  114. Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study
  115. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism
  116. Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE Database
  117. Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism
  118. Intermittent pneumatic compression plus pharmacological thromboprophylaxis to prevent deep vein thrombosis
  119. Venous thromboembolism in young adults: Findings from the RIETE registry
  120. The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease
  121. Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry
  122. Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis
  123. Reply to comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'
  124. Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
  125. Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis
  126. Mortality after pulmonary embolism in patients with diabetes. Findings from the RIETE registry
  127. D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis
  128. Outcomes beyond the Third Month of Anticoagulation in Patients Aged >75 Years with a First Episode of Unprovoked Venous Thromboembolism
  129. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
  130. Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry
  131. Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry
  132. Towards a precision medicine in venous thromboembolism associated to lung cancer
  133. Enfermedad tromboembólica venosa y cáncer: un reto para los clínicos
  134. Management appropriateness and outcomes of patients with acute pulmonary embolism
  135. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism
  136. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis
  137. Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism
  138. Awareness and understanding of venous thromboembolism in patients with cancer: data on 100 unselected cancer outpatients
  139. Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism
  140. Role of a clinical prediction score in a chronic thromboembolic pulmonary hypertension rule-out strategy
  141. Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism
  142. Prevalence of dual clarithromycin and metronidazole resistance in Helicobacter pylori estimated by molecular methods in Santiago, Chile
  143. Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score
  144. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
  145. Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study
  146. Características clínicas y pronóstico de la tromboembolia pulmonar secundaria al síndrome de clase turista
  147. Clinical Characteristics and Prognosis of Pulmonary Embolism Caused by Economy Class Syndrome
  148. Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism
  149. Real-life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants
  150. Correction:Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis
  151. Sex Differences in Patients With Occult Cancer After Venous Thromboembolism
  152. Clinically relevant bleeding and thrombotic events in non-cirrhotic splanchnic vein thrombosis. Long-term follow up
  153. Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis
  154. Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism
  155. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation
  156. Response
  157. The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site
  158. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE
  159. Calidad de vida en pacientes diagnosticados de embolia de pulmón aguda sintomática
  160. Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry
  161. Predictors of active cancer thromboembolic outcomes
  162. Noninvasive ventilation during the weaning process in chronically critically ill patients
  163. Unusual site thrombosis: splanchnic vein thrombosis, management in noncirrothic
  164. Search predictive factors of recurrence in venous thromboembolic disease associated with cancer after withdrawal of the anticoagulation. HISPALIS study
  165. Occult cancer in patients with acute venous thromboembolism: Why, when and where to investigate
  166. Treatment of venous thromboembolism in cancer patients with tinzaparin beyond 6 months. TiCAT study
  167. DVT Management and Outcome Trends, 2001 to 2014
  168. Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units
  169. Analysis of environmental risk factors for pulmonary embolism: A case-crossover study (2001–2013)
  170. Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective
  171. Trends in the Management and Outcomes of Acute Pulmonary Embolism
  172. Discharge Planning of Neuromuscular Patients with Noninvasive Mechanical Ventilation After Difficult Weaning from Invasive Mechanical Ventilation: From ICU to Home Care
  173. Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry
  174. High correlation between 2 flow cytometry platforms in the microparticles analysis using a new calibrated beads strategy
  175. Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice
  176. Respiratory intermediate care units: Noninvasive ventilation for severe acidotic patients
  177. Factors associated with mortality and survival in venous thromboembolism and hidden or concurrent cancer
  178. Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients
  179. The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism
  180. Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
  181. Corrigendum to ‘Rivaroxaban for the treatment of venous thromboembolism. A “real-life” perspective in 103 patients’ [Thrombosis Research 134 (2014) 617–621]
  182. A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis
  183. Identification of Low-Risk Patients with Acute Symptomatic Pulmonary Embolism for Outpatient Therapy
  184. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity
  185. Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism
  186. Venous thromboembolism in patients immobilised at home
  187. Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate
  188. Fondaparinux in the initial and long-term treatment of venous thromboembolism
  189. Gender differences in cancer patients with acute venous thromboembolism
  190. Lights and shadows of non-invasive mechanical ventilation for chronic obstructive pulmonary disease (COPD) exacerbations
  191. A Prognostic Score to Identify Low-risk Outpatients with Acute Deep Vein Thrombosis in the Lower Limbs
  192. Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy
  193. Rivaroxaban for the treatment of venous thromboembolism. A “real-life” perspective in 103 patients
  194. Outcomes in Neurosurgical Patients Who Develop Venous Thromboembolism
  195. C0396: Thrombophilia in Thrombosis and Cancer
  196. C0211: Prevalence of Metabolic Syndrome and All-Causes Mortality in Patients with Acute Symptomatic Venous Thromboembolism (VTE)
  197. C0246: Quality of Life in Acute Symptomatic Pulmonary Embolism and Low-Risk Prognosis
  198. C0306: Rivaroxaban for Treatment of Venous Thromboembolism. A Real-Life Perspective in 103 Patients
  199. D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer
  200. Pulmonary Embolism and Concomitant Paradoxical Embolism. A Case Report
  201. Tromboembolismo pulmonar y embolia paradójica concomitante. A propósito de un caso
  202. Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia pulmonar
  203. La escala predictiva de Khorana en pacientes con enfermedad tromboembólica venosa y cáncer
  204. Validación de 2 escalas clínicas pronósticas en pacientes con tromboembolia pulmonar aguda sintomática
  205. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism
  206. Normativa sobre el manejo de las complicaciones respiratorias de los pacientes con enfermedad neuromuscular
  207. Factors Associated with elevated Pulmonary Arterial Pressure Levels on the Echocardiographic Assessment in Patients with Prior Pulmonary Embolism
  208. Hipertensión pulmonar tromboembólica crónica
  209. Clinical Manifestations of Sarcoidosis
  210. Platelet count and outcome in patients with acute venous thromboembolism
  211. Análisis de 3 métodos para determinar el dímero D en pacientes con sospecha de trombosis venosa profunda
  212. Control ambulatorio de los pacientes con trombosis venosa profunda y cáncer: estudio de seguridad, costes e impacto presupuestario
  213. Chronic Thromboembolic Pulmonary Hypertension Due to Upper-Extremity Deep Vein Thrombosis Caused Thoracic Outlet Syndrome
  214. Hipertensión pulmonar tromboembólica crónica debida a trombosis venosa profunda de miembro superior por síndrome del desfiladero torácico
  215. Updated Guidelines for the Treatment of Pulmonary Sarcoidosis
  216. Effects of long-term anticoagulant therapy on levels of circulating microparticles in patients with deep venous thrombosis
  217. Malformaciones de la vena cava inferior como causa de trombosis venosa profunda. A propósito de dos casos
  218. Dyslipidemia as a long-term marker for survival in pulmonary embolism
  219. Lung cancer mortality in Spain: estimating the future burden to the year 2028
  220. Gender differences in lung cancer mortality trends in Andalusia 1975–2008: a joinpoint regression analysis
  221. Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism
  222. Right Atrium Mass in a 28-Year-Old Patient with Pulmonary Embolism Taking Contraceptives
  223. Utility of high-resolution computed tomography and BAL in cryptogenic organizing pneumonia
  224. Testing for occult cancer in patients with pulmonary embolism: Results from a screening program and a two-year follow-up survey
  225. Hallazgos en el lavado broncoalveolar de pacientes con enfermedad pulmonar intersticial difusa. Estudio de una cohorte prospectiva de 562 pacientes
  226. Hemorragia pulmonar por capilaritis pauciinmunitaria aislada con anticuerpos anticitoplasma de los neutrófilos negativos
  227. Síndrome hepatopulmonar en pacientes con hepatopatía avanzada: estudio de 24 casos
  228. Infección por Aspergillus terreus en pacientes con EPOC en tratamiento con corticoides. A propósito de tres casos
  229. Hemorragia digestiva baja asociada a celecoxib